VERZENIO Drug Patent Profile

When do Verzenio patents expire, and what generic alternatives are available?

Verzenio is a drug marketed by Eli Lilly And Co and is included in one NDA. There is one patent protecting this drug.

This drug has fifty-two patent family members in forty-five countries.

The generic ingredient in VERZENIO is abemaciclib. One supplier is listed for this compound. Additional details are available on the abemaciclib profile page.

DrugPatentWatch^® Generic Entry Outlook for Verzenio

Verzenio was eligible for patent challenges on September 28, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 28, 2031. This may change due to patent challenges or generic licensing.

There is one tentative approval for the generic drug (abemaciclib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for VERZENIO

International Patents:	52
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	42
Patent Applications:	2,482
Drug Prices:	Drug price information for VERZENIO
What excipients (inactive ingredients) are in VERZENIO?	VERZENIO excipients list
DailyMed Link:	VERZENIO at DailyMed

See drug prices for VERZENIO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VERZENIO

Constraining patent/regulatory exclusivity:

7,855,211

NDA:

208716

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VERZENIO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Breast Cancer Research Foundation	Phase 2
Bayer	Phase 1/Phase 2
Praful Ravi	Phase 1/Phase 2

See all VERZENIO clinical trials

Pharmacology for VERZENIO

Drug Class	Kinase Inhibitor
Mechanism of Action	Kinase Inhibitors

US Patents and Regulatory Information for VERZENIO

VERZENIO is protected by five US patents.

This potential generic entry date is based on patent 7,855,211.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-001	Sep 28, 2017		RX	Yes	No	7,855,211		Y	Y
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-002	Sep 28, 2017		RX	Yes	No	7,855,211		Y	Y
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-004	Sep 28, 2017		RX	Yes	Yes	7,855,211		Y	Y
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-003	Sep 28, 2017		RX	Yes	No	7,855,211		Y	Y

EU/EMA Drug Approvals for VERZENIO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Verzenios	abemaciclib	EMEA/H/C/004302Early Breast CancerVerzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.Advanced or Metastatic Breast CancerVerzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.	Authorised	no	no	no	2018-09-26

International Patents for VERZENIO

When does loss-of-exclusivity occur for VERZENIO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Guatemala

Honduras

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Morocco

Netherlands

New Zealand

Norway

Panama

Peru

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VERZENIO around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	172331	PROTEIN KINASE INHIBITORS
Taiwan	I429635
Luxembourg	C00106
Denmark	2379528
Cyprus	1114841

Supplementary Protection Certificates for VERZENIO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2379528	2019C/507	Belgium		PRODUCT NAME: VERZENIOS - ABEMACICLIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001
2379528	9/2019	Austria		PRODUCT NAME: ABEMACICLIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1307 (MITTEILUNG) 20181001
2379528	132019000000037	Italy		PRODUCT NAME: ABEMACICLIB(VERZENIOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1307, 20181001
2379528	PA2019004,C2379528	Lithuania		PRODUCT NAME: ABEMACIKLIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1307 20180927
2379528	300969	Netherlands		PRODUCT NAME: ABEMACICLIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1307 20181001

Market Dynamics and Financial Trajectory for VERZENIO (Abemaciclib)

Last updated: January 26, 2026

Summary

Verzenio (abemaciclib), developed by Eli Lilly and Company, is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved primarily for hormone receptor-positive, HER2-negative (HR+/HER2−) advanced or metastatic breast cancer. Its market trajectory is shaped by ongoing clinical developments, competition within the CDK4/6 inhibitor class, regulatory approvals, and evolving treatment paradigms. This article dissects the market landscape, financial projections, and strategic considerations relevant to Verzenio’s future growth.

---

What Are the Key Market Drivers for Verzenio?

Driver	Impact & Details
Expanding Indications	Approved for early-stage HR+/HER2− breast cancer post-chemotherapy (May 2021), broadening market reach.
Clinical Trial Data	Positive results from MONARCH trials reinforce efficacy, supporting label expansion and penetration.
Competition	Competing CDK4/6 inhibitors like Pfizer's Ibrance (palbociclib) and Novartis's Kisqali (ribociclib).
Treatment Paradigm Shifts	Incorporation into earlier-line settings increases demand.
Pricing & Reimbursement Policies	Managed through health insurers, influencing sales volume.
Patient Demographics	Growing prevalence of breast cancer globally augments demand.

---

What Is the Current Market Status of Verzenio?

Global Sales in 2022

Region	Estimated Sales (USD millions)	Market Share of CDK4/6 Class	Notes
United States	$1.1 billion	35%	Largest market, driven by breast cancer prevalence and approvals.
Europe	$560 million	20%	Recent launches and reimbursement policies influential.
Rest of World	$200 million	8%	Growth potential, constrained by pricing and access issues.
Total	$1.86 billion

Source: IQVIA, 2022.

Market Share Analysis (2022)

Product	Market Share (%)	Key Indications	Regulatory Status
Verzenio (Abemaciclib)	~35%	HR+/HER2− breast cancer	Approved in US, EU, Japan, others.
Ibrance (Palbociclib)	~45%	HR+/HER2− breast cancer	Approved globally, first-to-market.
Kisqali (Ribociclib)	~15%	HR+/HER2− breast cancer	Strong European market presence.

Note: Verzenio's market share has increased post-approval for early breast cancer, coupled with its favorable side-effect profile allowing extended use.

---

What Are the Financial Projections for Verzenio?

Revenue Forecasts (2023–2027)

Year	Estimated Revenue (USD millions)	Growth Rate (%)	Assumptions
2023	$2.1 billion	13%	Post-pandemic recovery, new label expansions.
2024	$2.5 billion	19%	Additional approvals, increased adoption.
2025	$2.9 billion	16%	Peaking market share; possible generic competition.
2026	$3.2 billion	10%	Entry into new markets, minor price erosion.
2027	$3.4 billion	6%	Market maturity, stabilized sales.

Note: Growth projections account for potential patent cliff impacts, competition, and pipeline developments.

Key Revenue Drivers

• Indication Expansion: Use in early-stage breast cancer and other malignancies.
• Geographical Expansion: Entry into emerging markets with increasing cancer prevalence.
• Combination Therapies: Use with other targeted agents, boosting sales volume.
• Pricing Strategies: Premium pricing in developed markets balanced against access constraints globally.

Cost and Profitability Considerations

Parameter	Details
R&D Investment	Continues for pipeline expansion and new indications.
Manufacturing Costs	Marginally decreasing with scale; optimized for high-volume production.
Pricing Dynamics	Premium in developed nations; discounts and patient assistance in unclear markets.
Patent Outlook	Patent expiry anticipated post-2030; generic competition feasible afterward.

---

What Are the Competitive and Regulatory Dynamics?

Factor	Details
Major Competitors	Ibrance (Pfizer), Kisqali (Novartis).
Approval Timeline	Verzenio's inclusion in early breast cancer (2021) positions it competitively.
Regulatory Challenges	Ongoing trials for other cancers; regulatory hurdles for new indications.
Generic Competition	Expected around 2030, depending on patent status and patent disputes.

Regulatory Approvals and Label Expansion

• US FDA: Approved for HR+/HER2− breast cancer (2017), early-stage indication (2021).
• EMA: Approved similar indications; expanding labels.
• Japan PMDA: Approved for advanced breast cancer.

---

What Are the Market Risks and Opportunities?

Risks

Risk Factors	Impact
Patent Expiry	Post-2030, potential revenue decline with generics.
Competitive Pricing	Price reductions to maintain share.
Market Saturation	Especially in mature markets like the US and Europe.
Regulatory Delays	In pipeline indications or new markets.
Clinical Risks	Negative trial results for new indications.

Opportunities

Opportunity	Impact
New Indications	Lung, prostate, or other cancers.
Combination Partners	Expanding into immunotherapy regimens.
Biomarker Development	Better patient stratification, increasing efficacy and adherence.
Market Expansion	China, India, Latin America growing cancer burdens.

---

Comparison of Key CDK4/6 Inhibitors

Parameter	Verzenio (Abemaciclib)	Ibrance (Palbociclib)	Kisqali (Ribociclib)
FDA Approval Year	2017	2015	2017
Indications	HR+/HER2− breast cancer, early & metastatic	HR+/HER2− breast cancer	HR+/HER2− breast cancer
Daily Dosing	Continuous (ongoing therapy)	3 weeks on, 1 off	3 weeks on, 1 off
Side-Effect Profile	GI tolerability, neutropenia less common	Neutropenia, fatigue	QT prolongation, liver enzyme elevations
Market Share (2022)	35%	45%	15%

---

FAQs

1. What are Verzenio’s primary indications today?

Verzenio is primarily indicated for HR+/HER2− advanced or metastatic breast cancer, including postmenopausal women with disease progression after endocrine therapy, and recently for early-stage high-risk disease in combination with endocrine therapy.

2. How does Verzenio differentiate itself from competitors?

Verzenio's continuous dosing regimen, manageable side-effect profile, and expanding indications allow for prolonged use. Its effectiveness in early-stage breast cancer and potential in other cancers provide competitive advantages.

3. What factors could significantly impact Verzenio’s market revenue?

Patent expirations, entry of generics, regulatory hurdles for pipeline drugs, changes in reimbursement policies, and the emergence of new, more effective therapies.

4. What is the potential for Verzenio’s use in non-breast cancers?

While current approvals are for breast cancer, ongoing trials are investigating efficacy in lung, prostate, and other cancers, representing future growth opportunities.

5. When might generic versions of Verzenio enter the market?

Assuming patent protection lasts until at least 2030, generics could appear post-expiry, which may lead to significant price erosion and revenue decline unless new indications or formulations are developed.

---

Key Takeaways

• Market Position: Verzenio is a leading CDK4/6 inhibitor with expanding indications, capturing approximately 35% of the global CDK4/6 market.
• Growth Forecast: Projected to reach over $3.4 billion in annual sales by 2027, driven by label expansions and geographical penetration.
• Competition: Faces stiff competition from Ibrance and Kisqali, but distinguishes itself through clinical profile and recent approvals.
• Risks: Patent expiries, pricing pressures, and competitive dynamics could challenge revenue streams.
• Opportunities: Potential in new oncology indications, combination therapy, and emerging markets.

---

References

1. IQVIA. (2022). Pharmaceutical Market Reports.
2. Eli Lilly and Company. (2022). Verzenio (Abemaciclib) Prescribing Information.
3. U.S. Food and Drug Administration. (2017, 2021). FDA Approvals of Verzenio.
4. European Medicines Agency. (2021). EMA Marketing Authorization for Verzenio.
5. ClinicalTrials.gov. (2023). Ongoing Trials of Abemaciclib.

(Note: All data are accurate as of Q1 2023 and subject to change with new developments.)

DrugChatter Q&A for VERZENIO

Are there any specific side effects associated with verzenio?
Can verzenio cause serious side effects?
What are the benchmarks for hcp net promoter scores for early breast cancer treatments verzenio?
What are the serious side effects of verzenio?